Generated by AI
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious and often underserved conditions. Its portfolio includes treatments for sleep disorders, epilepsy, oncology, and other specialized therapeutic areas, with products such as Xywav, Epidiolex, Zepzelca, Rylaze, and Vyxeos supporting patients who may have limited treatment options. Jazz Pharmaceuticals plc works across the United States, Europe, and other international markets, serving healthcare providers, hospitals, and patients through prescription medicines and specialty care solutions. The company emphasizes rare disease and oncology medicines, making it an important participant in the global specialty pharmaceutical market. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals plc maintains a focused business model centered on identifying, developing, and commercializing targeted therapies for complex medical needs.
WebsiteWaterloo Exchange
Dublin, D04 E5W7
Ireland
The latest articles about JAZZ.
Analyst sees Invesco Pharmaceuticals ETF as a long-term or tactical option; it beat XLV in the past year but lagged from July 2015 to July 2025.
Summary of Nov 2's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Investors talking about JAZZ also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.